Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Insmed Inc shares rose 2% premarket to $122.41 after the U.S. Food and Drug Administration granted priority review for its Arikayce drug to treat Mycobacterium avium complex lung disease. Full approval could expand its use to newly diagnosed patients. The FDA set a target decision date of Jan. 28, 2027. A late-stage st
FDA granted priority review to Insmed's SNDA for Arikayce to treat mac lung disease. The PDUFA target action date is January 28, 2027.
Insmed said the FDA granted Priority Review for its ARIKAYCE sNDA for MAC lung disease, with a PDUFA date of Jan. 28, 2027. Roth Capital cut its price target on INSM from $212 to $198.
FDA accepted Insmed's supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is set for Jan. 28, 2027. The filing seeks full approval, supported by Phase 3b ENCORE results.
FDA granted priority review to Insmed's supplemental new drug application (sNDA) for ARIKAYCE® (amikacin liposome inhalation suspension) to treat MAC lung disease. The Prescription Drug User Fee Act (PDUFA) target action date is January 28, 2027.